FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
